ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

Since our first ADC report over a year ago, our analysis has demonstrated significant doubts about all three leading TROP2 ADCs (AZN, GILD, MRK, SKB) achieving overall survival in first-line lung cancer, and we continue to see substantial hurdles for the class..